JO3489B1 - مركبات تراي أزولوبيريميدين واستخداماتها - Google Patents

مركبات تراي أزولوبيريميدين واستخداماتها

Info

Publication number
JO3489B1
JO3489B1 JOP/2015/0331A JOP20150331A JO3489B1 JO 3489 B1 JO3489 B1 JO 3489B1 JO P20150331 A JOP20150331 A JO P20150331A JO 3489 B1 JO3489 B1 JO 3489B1
Authority
JO
Jordan
Prior art keywords
triazolopyrimidine compounds
shireen
image002
appdata
prc2
Prior art date
Application number
JOP/2015/0331A
Other languages
English (en)
Inventor
Sendzik Martin
Mi Yuan
Huang Ying
Justin Gu Xiang-Ju
Man Chan Ho
Yu Zhengtian
Yue Ji (Jeff) Zhang
Zhao Kehao
Sun Yongfeng
Zhang Hailong
Li Ling
Zhang Man
Zhang Qiong
Qi Wei
Wang Long
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3489B1 publication Critical patent/JO3489B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركب من الصيغة (I)، أو ملح مقبول صيدلانيا منه، والذي اتضح أنه مفيد في علاج مرض أو اضطراب ناتج عن PRC2: حيث R1، وR2، وR3، وR4، وR5، وn هي كما هي محددة هن <img src="file:///C:/Users/shireen.s/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />
JOP/2015/0331A 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها JO3489B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
JO3489B1 true JO3489B1 (ar) 2020-07-05

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0331A JO3489B1 (ar) 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها

Country Status (40)

Country Link
US (5) US10220036B2 (ar)
EP (1) EP3237418B1 (ar)
JP (1) JP6736559B2 (ar)
KR (1) KR102534028B1 (ar)
CN (1) CN107108637B (ar)
AU (1) AU2015370524B2 (ar)
BR (1) BR112017010354B8 (ar)
CA (1) CA2969090C (ar)
CL (1) CL2017001572A1 (ar)
CO (1) CO2017005992A2 (ar)
CR (1) CR20170285A (ar)
CY (1) CY1121901T1 (ar)
DK (1) DK3237418T3 (ar)
DO (1) DOP2017000149A (ar)
EA (1) EA032416B1 (ar)
EC (1) ECSP17047153A (ar)
ES (1) ES2722048T3 (ar)
GT (1) GT201700146A (ar)
HR (1) HRP20190805T1 (ar)
HU (1) HUE043060T2 (ar)
IL (1) IL252135B (ar)
JO (1) JO3489B1 (ar)
LT (1) LT3237418T (ar)
ME (1) ME03385B (ar)
MX (1) MX2017008529A (ar)
MY (1) MY186837A (ar)
NZ (1) NZ731664A (ar)
PE (1) PE20171307A1 (ar)
PH (1) PH12017501016A1 (ar)
PL (1) PL3237418T3 (ar)
PT (1) PT3237418T (ar)
RS (1) RS58679B1 (ar)
SG (1) SG11201703880VA (ar)
SI (1) SI3237418T1 (ar)
SV (1) SV2017005472A (ar)
TN (1) TN2017000204A1 (ar)
TW (1) TWI694076B (ar)
UA (1) UA120945C2 (ar)
UY (1) UY36462A (ar)
WO (1) WO2016103155A1 (ar)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534028B1 (ko) * 2014-12-23 2023-05-19 노파르티스 아게 트리아졸로피리미딘 화합물 및 그의 용도
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3472168B1 (en) * 2016-06-20 2024-01-10 Novartis AG Crystalline forms of triazolopyrimidine compound
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
JP6916279B2 (ja) 2016-07-12 2021-08-11 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
EP4230623A3 (en) 2017-01-23 2023-10-11 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
WO2018136265A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
EP3575301A4 (en) * 2017-03-16 2020-08-05 Jiangsu Hengrui Medicine Co., Ltd. HETEROARYL [4,3-C] PYRIMIDINE-5-AMINE DERIVATIVE, PROCESS FOR PREPARATION AND MEDICAL USES
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CA3078565A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
EP3724189B1 (en) * 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
CN111630042A (zh) 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
CA3089639C (en) 2018-01-31 2024-06-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
EP3938050A1 (en) 2019-03-15 2022-01-19 Fulcrum Therapeutics, Inc. Macrocyclic azolopyridine derivatives as eed and prc2 modulators
CA3135449A1 (en) * 2019-04-03 2020-10-08 Tera Stone Co., Ltd Triazolopyrimidines based on thymine nucleobase and methods for producing them
EP3959214A1 (en) * 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3969639A1 (en) 2019-05-13 2022-03-23 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
JP2022535267A (ja) * 2019-06-05 2022-08-05 アセネックス インコーポレイテッド 乾癬を治療および／または予防する方法
AU2020288563A1 (en) * 2019-06-05 2022-01-06 Mirati Therapeutics, Inc. Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer
AU2020332462B2 (en) * 2019-08-22 2023-08-17 Shanghai Blueray Biopharma Co., Ltd. Azaheteroaryl compound and application thereof
WO2021057853A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
CN114929707B (zh) * 2019-11-01 2024-04-09 上海科技大学 Eed抑制剂及其制备方法和用途
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
EP4149932A4 (en) * 2020-05-11 2024-06-26 Ascentage Pharma (Suzhou) Co., Ltd. PROCESS FOR PREPARING (5-FLUOR-2, 3-DIHYDROBENZOFURAN-4-YL) METHANAMINE OR ITS SALT AND INTERMEDIATE PRODUCTS THEREOF
EP4157279A1 (en) 2020-05-28 2023-04-05 Novartis AG Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
WO2003034997A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
CN104876904A (zh) 2002-03-08 2015-09-02 卫材R&D管理株式会社 用作医药品的大环化合物
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
ATE449168T1 (de) 2004-06-01 2009-12-15 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (ar) 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
ES2593279T3 (es) 2007-08-29 2016-12-07 Methylgene Inc. Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
ES2439705T3 (es) 2007-10-25 2014-01-24 Genentech, Inc. Proceso para la preparación de compuestos de tienopirimidina
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
US8895526B2 (en) 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
MX2012012966A (es) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
US20140213475A1 (en) 2011-07-14 2014-07-31 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
CA2867282C (en) 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
KR102219441B1 (ko) 2013-02-11 2021-02-23 콘스텔레이션 파마슈티칼스, 인크. 메틸 변형 효소 조절제, 이의 조성물 및 용도
BR112015022604A2 (pt) 2013-03-14 2017-10-24 Genentech Inc usos de um modulador de modificador de cromatina e um antagonista de egfr
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN107108385B (zh) 2014-11-14 2021-09-24 巴斯夫欧洲公司 作为硝化抑制剂的苄基炔丙基醚
NO3033944T3 (ar) 2014-12-16 2018-07-14
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102534028B1 (ko) * 2014-12-23 2023-05-19 노파르티스 아게 트리아졸로피리미딘 화합물 및 그의 용도
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
CR20170285A (es) 2017-08-21
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
PT3237418T (pt) 2019-05-23
UA120945C2 (uk) 2020-03-10
EP3237418A1 (en) 2017-11-01
SG11201703880VA (en) 2017-07-28
UY36462A (es) 2016-07-29
ES2722048T3 (es) 2019-08-07
PH12017501016B1 (en) 2017-12-11
PL3237418T3 (pl) 2019-07-31
AU2015370524A1 (en) 2017-06-01
CN107108637A (zh) 2017-08-29
TN2017000204A1 (en) 2018-10-19
GT201700146A (es) 2019-06-12
AU2015370524B2 (en) 2018-11-01
SV2017005472A (es) 2018-06-12
TW201629065A (zh) 2016-08-16
IL252135A0 (en) 2017-07-31
CA2969090C (en) 2023-05-02
RS58679B1 (sr) 2019-06-28
KR102534028B1 (ko) 2023-05-19
US9580437B2 (en) 2017-02-28
JP2018500342A (ja) 2018-01-11
HUE043060T2 (hu) 2019-07-29
JP6736559B2 (ja) 2020-08-05
CL2017001572A1 (es) 2018-01-12
BR112017010354B8 (pt) 2022-10-18
ECSP17047153A (es) 2019-02-28
MX2017008529A (es) 2017-10-25
HRP20190805T1 (hr) 2019-06-28
US20200323859A1 (en) 2020-10-15
CY1121901T1 (el) 2020-10-14
KR20170095882A (ko) 2017-08-23
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
DOP2017000149A (es) 2017-07-15
EP3237418B1 (en) 2019-01-30
EA032416B1 (ru) 2019-05-31
US20160176882A1 (en) 2016-06-23
US20170348312A1 (en) 2017-12-07
WO2016103155A1 (en) 2016-06-30
IL252135B (en) 2020-06-30
BR112017010354A2 (pt) 2017-12-26
PH12017501016A1 (en) 2017-12-11
US11931363B2 (en) 2024-03-19
LT3237418T (lt) 2019-05-10
DK3237418T3 (da) 2019-05-13
CO2017005992A2 (es) 2017-10-20
BR112017010354B1 (pt) 2022-09-20
US11207325B2 (en) 2021-12-28
EA201791420A1 (ru) 2017-10-31
SI3237418T1 (sl) 2019-06-28
CA2969090A1 (en) 2016-06-30
US20230033320A1 (en) 2023-02-02
NZ731664A (en) 2024-02-23
MY186837A (en) 2021-08-25
CN107108637B (zh) 2019-10-29
ME03385B (me) 2020-01-20

Similar Documents

Publication Publication Date Title
JO3489B1 (ar) مركبات تراي أزولوبيريميدين واستخداماتها
JO3648B1 (ar) عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
PH12016500225B1 (en) Novel quinoline-substituted compound
JO3583B1 (ar) مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EA201692219A1 (ru) Способы получения противовирусных соединений
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MD20160017A2 (ro) Polimorf al inhibitorilor SYK
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
PH12017500095A1 (en) Imidazopyridazine compounds
JO3579B1 (ar) مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
MA38404A1 (fr) Nouveaux dérivés de pyridine
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
JO3610B1 (ar) مشتقات كربوكساميد
EA201692270A1 (ru) Производные нафтиридиндиона